SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001725160-21-000106
Filing Date
2021-05-04
Accepted
2021-05-03 17:33:23
Documents
11

Document Format Files

Seq Description Document Type Size
1 S-3 zentalis-sx3universalshelf.htm S-3 421348
2 EX-1.2 exhibit12-zentalisatmxsale.htm EX-1.2 284306
3 EX-4.3 zntl-formofindentureex43fi.htm EX-4.3 460028
4 EX-5.1 zntl-51opinionuniversals.htm EX-5.1 18854
5 EX-23.2 s-3consentxeyxq22021.htm EX-23.2 2448
6 image_01a.jpg GRAPHIC 38416
7 GRAPHIC zntl-51opinionuniversals001.jpg GRAPHIC 215460
8 GRAPHIC zntl-51opinionuniversals002.jpg GRAPHIC 279761
9 GRAPHIC zntl-51opinionuniversals003.jpg GRAPHIC 307162
10 GRAPHIC zntl-51opinionuniversals004.jpg GRAPHIC 330474
11 GRAPHIC zntl-51opinionuniversals005.jpg GRAPHIC 186388
  Complete submission text file 0001725160-21-000106.txt   3056963
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-255737 | Film No.: 21884909
SIC: 2834 Pharmaceutical Preparations